Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache

Clinical Pharmacokinetics

Volumn 10, Issue 4, 1985, Pages 334-352

  Perrin, V L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BELLADONNA ALKALOID; CAFERGOT; CAFFEINE; DEXTROPROPOXYPHENE; DHC 50; DIHYDROERGOTAMINE; DIHYDROERGOTAMINE MESILATE; EC 112; EC 222; ECB 115; ECBP 163; ERGOMETRINE; ERGOTAMINE; ERGOTAMINE TARTRATE; ISOMETHEPTENE; MIDRID; PENTOBARBITAL; PLACEBO; RADIOISOTOPE; TOLFENAMIC ACID; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADVERSE DRUG REACTION; ARTERY SPASM; BIOAVAILABILITY; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLUSTER HEADACHE; COLD LIMB; DHC 50; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; EC 222; ECB 115; ECBP 163; ERGOTAMINE H 3; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTOXICATION; MIGRAINE; MUSCLE; MYALGIA; NAUSEA; PARESTHESIA; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SEROTONINERGIC SYSTEM; THERAPY; VASOCONSTRICTION; VOMITING; WEAKNESS;

ADMINISTRATION, ORAL; CAFFEINE; CEREBROVASCULAR CIRCULATION; CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER HEADACHE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERGOTAMINE; HUMAN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTESTINAL ABSORPTION; KINETICS; MALE; MIGRAINE; RADIOIMMUNOASSAY; RECTUM; REGIONAL BLOOD FLOW; TONGUE; VASCULAR HEADACHES;

EID: 0021856419     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198510040-00004     Document Type: Review

References (75)

1. Therapeutische Mitteilungen. Orale Behandlung des Migräneanfalls
2. Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed
3. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man
4. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration
5. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication
6. Ergotamine abuse: Results of ergotamine discontinuation with special reference to the plasma concentrations
7. Ergotamine headache
8. A new look at the use of ergotamine
9. Raphe inhibition of sympathetic preganglionic neurons
10. Central serotonin and cardiovascular control
11. Treatment of severe migraine with Cafergot
12. Clinical trial of inhaled ergotamine tartrate in migraine
13. Le tartrate d’ergotamine cafeiné, traitement de l’acces migraineux
14. Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability
15. Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection
16. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study
17. Low biological availability of ergotamine tartrate after oral dosing in cluster headache
18. Treatment of the migraine attack
19. Treatment of headache
20. Recent advances in treatment of migraine
21. Cafergot suppositories in migraine
22. Ergotamine toxicity and serum concentrations of ergotamine in migraine patients
23. The systemic availability of ergotamine tartrate given by three different routes of administration to healthy volunteers
24. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine
25. Aerosol ergotamine tartrate for migraine and Horton’s syndrome
26. Mechanism of migraine headache and action of ergotamine tartrate
27. Mechanism of migraine headache and action of ergotamine tartrate
28. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks
29. Tolfenamic acid is as effective as ergotamine during migraine attacks
30. Pathogenesis of migraine
31. Clinical aspects of pharmacokinetics of ergotamine
32. Clinical observation of the use of EC 110, a new agent for the treatment of headache
33. Ergotamine in plasma and CSF after i.m. and rectal administration to humans
34. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers
35. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers
36. Clinical observations on the rectal and oral use of various ergot derivatives in headache
37. Ergonovine versus ergotamine as terminator of headaches
38. Experience with ergotamine tartrate in 120 patients with migraine
39. Treatment of headache with ergotamine-caffeine suppositories
40. Effectiveness of aerosol administration of ergotamine tartrate in migraine headache
41. The treatment of headache with Cafergot suppositories
42. Studies on the 5-HT receptor in vascular smooth muscle
43. Vascular effects of ergot alkaloids: A study on human basilar arteries
44. Basic pharmacological properties
45. Ergot alkaloids: Hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine
46. Changes in cerebral blood flow during a migraine attack
47. Ergotamine absorption and toxicity
48. A study of migraine pharmacotherapy
49. Termination of one thousand attacks of migraine with ergotamine tartrate
50. Studies on headache: Central versus peripheral action of ergotamine tartrate and its relevance to the therapy of migraine headache
51. Les cephalees ‘vasculaires’ et leur traitement par une association d’ergotamine et de caféine
52. Assessment of extracranial cerebral vessels in patients with migraine after administration of ergotamine tartrate using Doppler ultrasound
53. Serotonin neurons project to small blood vessels in the brain
54. The use of experimental suppositories in treating refractory migraine
55. 9, 10-Dihydroergotamine: Production of antibodies and radioimmunoassay
56. 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls
57. Historical development of the ergot therapy of migraine
58. 133Xe inhalation method
59. Effect of caffeine on intestinal absorption of ergotamine in man
60. A clinical report on the relief of headaches non-responsive to analgesics
61. Intrahypothalamic serotonin and cardiovascular control in rats
62. The effect of ergotamine and methysergide on serotonin metabolism in the rat brain
63. Ergotamine tartrate inhalation: A new approach to the management of recurrent vascular headaches
64. The action of ergotamine on the distribution of carotid blood flow — the migraine shunt theory revisited
65. Buccal absorption of ergotamine
66. Ergotamine tartrate and caffeine (EC112) in migraine headaches
67. A particular variety of headache
68. Clinical pharmacology of ergotamine studied with a high performance liquid Chromatographic meihod
69. General and regional haemodynamic effects of intravenous ergotamine in man
70. Ergotamine-induced headaches
71. Controlled clinical trial of ergotamine tartrate
72. Ergotamine tartrate in the treatment of migraine
73. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine